Targeted Oncology3h
Usmani Projects a Future of CAR T in Community for Myeloma and Other Cancers
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
Targeted Oncology3h
FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia
Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...
Targeted Oncology5h
Survival Gains and Challenges: The CROSS Trial in GEJ Cancer
Yanghee Woo, MD, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction ...
Targeted Oncology7h
Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
Targeted Oncology10h
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
Targeted Oncology9h
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly ...